Phase I Study of NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma, for Whom Treatment With Ipilimumab is Indicated
Phase of Trial: Phase I
Latest Information Update: 20 Jun 2016
At a glance
- Drugs Cancer vaccine NY-ESO-1 (Primary) ; Ipilimumab (Primary) ; Montanide ISA-51 (Primary) ; Poly ICLC (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 16 Jun 2016 Planned End Date changed from 1 May 2016 to 1 Dec 2016.
- 16 Jun 2016 Status changed from active, no longer recruiting to discontinued.